Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
98 hedge funds and large institutions have $83.8M invested in Unity Biotechnology in 2021 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 23 closing their positions.
197% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $474K
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
7% more funds holding
Funds holding: 92 → 98 (+6)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.41% less ownership
Funds ownership: 3.71% → 3.3% (-0.41%)
31% less capital invested
Capital invested by funds: $122M → $83.8M (-$38M)
33% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.6M |
| 2 |
Millennium Management
New York
|
+$2.92M |
| 3 |
Renaissance Technologies
New York
|
+$2.47M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.11M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.45M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$7.22M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.38M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.47M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.2M |
UBX Hedge Fund Activity: Q2 2021 in Review
98 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2021, worth a combined $83.8M — down 31% from $122M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new UBX positions and 23 closed out — a net gain of 6 holders — while 16 added to existing stakes and 24 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.6M. The largest seller was BlackRock, cutting an estimated $9.45M.
- 98 institutional investors held Unity Biotechnology (UBX) as of Q2 2021, up from 92 in Q1 2021.
- Funds reported $83.8M of Unity Biotechnology stock for Q2 2021, down 31% quarter-over-quarter.
- 29 funds opened new Unity Biotechnology positions in Q2 2021 and 23 closed out, a net change of +6 holders.
- The largest Unity Biotechnology buyer in Q2 2021 was Morgan Stanley, an estimated $3.6M added.
- The largest Unity Biotechnology seller in Q2 2021 was BlackRock, an estimated $9.45M sold.
Based on aggregated 13F filings for Q2 2021.